Navigation Links
PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
Date:3/23/2009

OSLO, March 23 /PRNewswire/ -- PCI Biotech Holding ASA, the Norwegian drug delivery company, and siRNAsense AS, the Norwegian drug development company, today announced that a PCI Biotech-led consortium focused on effective siRNA cancer drug delivery has been ranked 3rd out of more than 300 European projects and will receive EUR 1.1 million in funding from the EU Eurostars Programme.

The consortium comprises three companies PCI Biotech, SpectraCure and siRNAsense and the project is entitled "Photochemical Internalisation for delivery of short interfering RNA (siRNA) - towards safe and specific cancer therapy". Competition was extremely fierce. All projects were assessed by carefully selected independent technical experts and an independent evaluation panel. They were then ranked across all industries based on an assessment of the project, technology and innovation, and market and competitiveness factors. The PCI Biotech-led project was ranked as number three of the 317 submitted applications. The three partners are contributing equally to the consortium.

The proposal came about because PCI Biotech, SpectraCure and siRNAsense were already aiming to develop their complementary technologies to fulfil unmet medical need in several disease areas, with cancer being a current focus area. The Eurostars' funding will now be used to develop a method for efficient light-directed delivery of siRNA to a variety of tumours. SiRNAs are compounds regulating gene expression in cells, with significant therapeutic and commercial potential; the realization of which urgently requires effective technologies for delivering siRNA into cells in the body.

Dr. Per Walday, CEO of PCI Biotech, comments: "The funding from Eurostars is an important milestone for PCI Biotech. The support provides financial backing in a critical phase of the development of the PCI technology, as well as an international collaborative opportunity between companies with innovative complementary technologies. We are very pleased that independent European experts share our view that photochemical internalisation has the potential to play an important role in future medical treatments based on siRNA."

Dr Hanne Mette Kristensen, CEO of siRNAsense adds: "This collaboration project will allow us to continue developing exciting new drug candidates for cancer indications. RNA interference is a new and very promising field, where delivery of the drug represents a big challenge. This funding will enable us to continue our investigation of effective ways of delivering siRNA based drugs to solid tumours. Combining PCI Biotech's technology with SpectraCure's fibreoptic dosimetry system will make it possible to enable homogeneous penetration throughout the various tumour layers."

    Corporate Inquiries:

    PCI Biotech ASA
    Per Walday
    tel: +47(0)23-25-4000
    Email: per.walday@pcibiotech.no

    siRNAsense AS
    Hanne Mette D. Kristensen
    tel: +47(0)22-95-8192
    E-mail: hannemette@sirnasense.com


'/>"/>
SOURCE PCI Biotech Holding ASA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NewCardio Joins the Cardiac Safety Research Consortium
2. Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts
3. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
4. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
5. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
6. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
7. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
8. UTSA/UT lead national nanoscience consortium
9. Consortium publishes Phase II map of human genetic variation
10. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... NeuMedics Inc. ... podium presentation at Life Science Innovation Northwest on June 2, 2016. The session begins ... NeuMedics compound and propriety microemulsion can be successfully used as a topical agent and ...
(Date:5/27/2016)... , May 27, 2016 At ... investors playing in this space know that volatility is what ... featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... Lpath Inc. (NASDAQ: LPTN ), and Heat Biologics ... gain access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... variety of fracture-specific plating options designed to address fractures of the distal tibia ... solutions. , The Acumed Ankle Plating System 3 is composed of seven plate ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):